Genovis

Genovis Current Assets

The Current Assets of Genovis (GENO.ST) as of Oct 18, 2026 is 190.85 M SEK. In the previous year, Current Assets was 207.12 M SEK — a change of -7.85% (lower).

Current Assets

190.85 MSEK

YoY

-7.85%

Last updated:

Current Assets of Genovis is 2025 190.85 M SEK. Current Assets of Genovis was 2024 207.12 M SEK. It decreases by -7.85% lower compared to the previous year.

The Genovis Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
31.68 M SEK
Jan 1, 2019
35.26 M SEK
Jan 1, 2020
73.09 M SEK
Jan 1, 2021
106.52 M SEK
Jan 1, 2022
108.64 M SEK
Jan 1, 2023
160.69 M SEK
Jan 1, 2024
207.12 M SEK
Jan 1, 2025
190.85 M SEK
The Genovis Current Assets history
YEARCurrent AssetsYoY
190.85 MSEK-7.85%
207.12 MSEK+28.89%
160.69 MSEK+47.91%
108.64 MSEK+1.99%
106.52 MSEK+45.73%
73.09 MSEK+107.26%
35.26 MSEK+11.30%
31.68 MSEK+45.14%
21.83 MSEK+10.36%
19.78 MSEK+30.03%
15.21 MSEK+42.93%
10.64 MSEK-81.90%
58.80 MSEK+484.03%
10.07 MSEK-7.34%
10.87 MSEK+97.64%
5.50 MSEK+188.03%
1.91 MSEK+66.93%
1.14 MSEK+3.94%
1.10 MSEK-94.05%
18.49 MSEK+921.55%
1.81 MSEK+54.70%
1.17 MSEK-28.22%
1.63 MSEK-40.94%
2.76 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genovis Stock analysis

What does Genovis do? Genovis AB is a Swedish company that offers biotechnology solutions for drug research and diagnostic industries. The company was founded in Lund, Sweden in 1999 and currently employs over 30 employees. Genovis began with the development of enzymes for protein-based therapeutics, but over time expanded its business to include enzymes for improved analysis methods in mass spectrometry. Genovis has become a leading provider of innovative enzyme solutions and proteomics tools for biomedical research. The company's business model is based on providing specially developed enzymes and proteomics tools to companies in drug research and diagnostic industries. Genovis has two main business areas: marketing enzymes and providing peptide synthesis services. The first business area is the marketing of enzymes for the separation of glycosylated proteins in mass spectrometry. The company develops and produces these enzymes for various applications such as Alzheimer's research, cancer research, and infectious diseases. Genovis is also an important provider of enzymes for the investigation of antibody-drug conjugates used in novel therapeutic approaches. The second business area is providing peptide synthesis services. The company also has a diversified biotechnology infrastructure and offers analysis and synthesis services for peptides in various fields, such as immunotherapy and diagnostics. Genovis' product portfolio includes a variety of enzymes that have broad application in drug research and diagnostic industries. This includes enzymes for antibody proteolysis, enzymes for the synthesis of glycoconjugates, and enzymes for conjugated protein analysis. In addition, the company also offers specialized kits for protein analysis. Genovis kits always include all necessary components such as proteases, buffer systems, and instructions to conduct the offered experiments. In conclusion, Genovis is a leading company in the biotechnology industry that offers innovative enzyme solutions and proteomics tools for a variety of applications in medical research and diagnostics. With its diversified biotechnology infrastructure and dedicated employees, the company can meet the growing needs of its customers in the science and industry sectors and has become a key partner in the healthcare industry. Genovis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genovis stock

Current Assets of Genovis is 190.85 M SEK in 2025.

Current Assets of Genovis changed from 207.12 M SEK to 190.85 M SEK, representing a -7.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Genovis since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Genovis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genovis

All Key Metrics — Genovis